Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anette Duensing

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Cancer Research|December 24, 2009
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cellsSebastian Bauer, Joshua A Parry, Thomas Mühlenberg, et al.
Urologic Oncology|June 12, 2018
FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancerCarine Pecqueux, Aysenur Arslan, Martina Heller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindredFrederick P Li, Jonathan A Fletcher, Michael C Heinrich, et al.
Oncotarget|December 15, 2016
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylateJessica L Rausch, Sergei Boichuk, Areej A Ali, et al.
Scientific Reports|July 6, 2017
Mutations in BRCA2 and taxane resistance in prostate cancerCathleen Nientiedt, Martina Heller, Volker Endris, et al.
The Journal of Biological Chemistry|September 5, 2020
Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cellsAbigail Allen, David Gau, Paul Francoeur, et al.
Science (New York, N.Y.)|January 11, 2003
PDGFRA activating mutations in gastrointestinal stromal tumorsMichael C Heinrich, Christopher L Corless, Anette Duensing, et al.
Cancer Immunology, Immunotherapy : CII|December 23, 2022
BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept studyJana Friedhoff, Felix Schneider, Christina Jurcic, et al.
Diagnostics (Basel, Switzerland)|April 13, 2024
PD-L1 as a Urine Biomarker in Renal Cell Carcinoma-A Case Series and Proof-of-Concept StudyPhilipp Reimold, Georgi Tosev, Adam Kaczorowski, et al.
Cancer Research|June 22, 2013
The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosisSergei Boichuk, Joshua A Parry, Kathleen R Makielski, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Cancer Research|December 24, 2009
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cellsSebastian Bauer, Joshua A Parry, Thomas Mühlenberg, et al.
Urologic Oncology|June 12, 2018
FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancerCarine Pecqueux, Aysenur Arslan, Martina Heller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindredFrederick P Li, Jonathan A Fletcher, Michael C Heinrich, et al.
Oncotarget|December 15, 2016
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylateJessica L Rausch, Sergei Boichuk, Areej A Ali, et al.
Scientific Reports|July 6, 2017
Mutations in BRCA2 and taxane resistance in prostate cancerCathleen Nientiedt, Martina Heller, Volker Endris, et al.
The Journal of Biological Chemistry|September 5, 2020
Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cellsAbigail Allen, David Gau, Paul Francoeur, et al.
Science (New York, N.Y.)|January 11, 2003
PDGFRA activating mutations in gastrointestinal stromal tumorsMichael C Heinrich, Christopher L Corless, Anette Duensing, et al.
Cancer Immunology, Immunotherapy : CII|December 23, 2022
BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept studyJana Friedhoff, Felix Schneider, Christina Jurcic, et al.
Diagnostics (Basel, Switzerland)|April 13, 2024
PD-L1 as a Urine Biomarker in Renal Cell Carcinoma-A Case Series and Proof-of-Concept StudyPhilipp Reimold, Georgi Tosev, Adam Kaczorowski, et al.
Cancer Research|June 22, 2013
The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosisSergei Boichuk, Joshua A Parry, Kathleen R Makielski, et al.
Pageof 8